119 related articles for article (PubMed ID: 14692524)
1. Anti-B4 blocked ricin post chemotherapy in patients with chronic lymphocytic leukemia--long-term follow-up of a monoclonal antibody-based approach to residual disease.
Tsimberidou AM; Giles FJ; Kantarjian HM; Keating MJ; O'Brien SM
Leuk Lymphoma; 2003 Oct; 44(10):1719-25. PubMed ID: 14692524
[TBL] [Abstract][Full Text] [Related]
2. A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma.
Grossbard ML; Multani PS; Freedman AS; O'Day S; Gribben JG; Rhuda C; Neuberg D; Nadler LM
Clin Cancer Res; 1999 Sep; 5(9):2392-8. PubMed ID: 10499609
[TBL] [Abstract][Full Text] [Related]
3. Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study.
Longo DL; Duffey PL; Gribben JG; Jaffe ES; Curti BD; Gause BL; Janik JE; Braman VM; Esseltine D; Wilson WH; Kaufman D; Wittes RE; Nadler LM; Urba WJ
Cancer J; 2000; 6(3):146-50. PubMed ID: 10882329
[TBL] [Abstract][Full Text] [Related]
4. Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311.
Szatrowski TP; Dodge RK; Reynolds C; Westbrook CA; Frankel SR; Sklar J; Stewart CC; Hurd DD; Kolitz JE; Velez-Garcia E; Stone RM; Bloomfield CD; Schiffer CA; Larson RA
Cancer; 2003 Mar; 97(6):1471-80. PubMed ID: 12627512
[TBL] [Abstract][Full Text] [Related]
5. Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma.
Multani PS; O'Day S; Nadler LM; Grossbard ML
Clin Cancer Res; 1998 Nov; 4(11):2599-604. PubMed ID: 9829722
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of anti-B4-blocked ricin in pediatric patients with leukemia and lymphoma.
Dinndorf P; Krailo M; Liu-Mares W; Frierdich S; Sondel P; Reaman G
J Immunother; 2001; 24(6):511-6. PubMed ID: 11759074
[TBL] [Abstract][Full Text] [Related]
7. Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms.
Grossbard ML; Lambert JM; Goldmacher VS; Spector NL; Kinsella J; Eliseo L; Coral F; Taylor JA; Blättler WA; Epstein CL
J Clin Oncol; 1993 Apr; 11(4):726-37. PubMed ID: 7683045
[TBL] [Abstract][Full Text] [Related]
8. Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion.
Grossbard ML; Freedman AS; Ritz J; Coral F; Goldmacher VS; Eliseo L; Spector N; Dear K; Lambert JM; Blättler WA
Blood; 1992 Feb; 79(3):576-85. PubMed ID: 1370636
[TBL] [Abstract][Full Text] [Related]
9. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
Shah SA; Halloran PM; Ferris CA; Levine BA; Bourret LA; Goldmacher VS; Blättler WA
Cancer Res; 1993 Mar; 53(6):1360-7. PubMed ID: 7680284
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma.
Grossbard ML; Gribben JG; Freedman AS; Lambert JM; Kinsella J; Rabinowe SN; Eliseo L; Taylor JA; Blättler WA; Epstein CL
Blood; 1993 May; 81(9):2263-71. PubMed ID: 8481509
[TBL] [Abstract][Full Text] [Related]
11. Anti-B4-blocked ricin: a phase II trial of 7 day continuous infusion in patients with multiple myeloma.
Grossbard ML; Fidias P; Kinsella J; O'Toole J; Lambert JM; Blattler WA; Esseltine D; Braman G; Nadler LM; Anderson KC
Br J Haematol; 1998 Jul; 102(2):509-15. PubMed ID: 9695966
[TBL] [Abstract][Full Text] [Related]
12. Correlation between in vivo toxicity and preclinical in vitro parameters for the immunotoxin anti-B4-blocked ricin.
Grossbard ML; Lambert JM; Goldmacher VS; Blättler WA; Nadler LM
Cancer Res; 1992 Aug; 52(15):4200-7. PubMed ID: 1379121
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the systemic toxicity and pharmacokinetics of the immunoconjugate anti-B4-blocked ricin in non-human primates. Delivered by multiple bolus injections and by continuous infusion.
Shah SA; Lambert JM; Goldmacher VS; Esber HJ; Levin JL; Chungi V; Zutshi A; Braman GM; Ariniello PD; Taylor JA
Int J Immunopharmacol; 1993 Aug; 15(6):723-36. PubMed ID: 7691767
[TBL] [Abstract][Full Text] [Related]
14. A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254.
Furman RR; Grossbard ML; Johnson JL; Pecora AL; Cassileth PA; Jung SH; Peterson BA; Nadler LM; Freedman A; Bayer RL; Bartlett NL; Hurd DD; Cheson BD; ;
Leuk Lymphoma; 2011 Apr; 52(4):587-96. PubMed ID: 21275630
[TBL] [Abstract][Full Text] [Related]
15. Immunotoxin combined with chemotherapy for patients with AIDS-related non-Hodgkin's lymphoma.
Scadden DT; Schenkein DP; Bernstein Z; Luskey B; Doweiko J; Tulpule A; Levine AM
Cancer; 1998 Dec; 83(12):2580-7. PubMed ID: 9874466
[TBL] [Abstract][Full Text] [Related]
16. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia.
O'Brien SM; Kantarjian HM; Thomas DA; Cortes J; Giles FJ; Wierda WG; Koller CA; Ferrajoli A; Browning M; Lerner S; Albitar M; Keating MJ
Cancer; 2003 Dec; 98(12):2657-63. PubMed ID: 14669286
[TBL] [Abstract][Full Text] [Related]
17. Elimination of B-lineage leukemia and lymphoma cells from bone marrow grafts using anti-B4-blocked-ricin immunotoxin.
Roy DC; Perreault C; Bélanger R; Gyger M; Le Houillier C; Blättler WA; Lambert JM; Ritz J
J Clin Immunol; 1995 Jan; 15(1):51-7. PubMed ID: 7539011
[TBL] [Abstract][Full Text] [Related]
18. Conjugation of blocked ricin to an anti-CD19 monoclonal antibody increases antibody-induced cell calcium mobilization and CD19 internalization.
Goulet AC; Goldmacher VS; Lambert JM; Baron C; Roy DC; Kouassi E
Blood; 1997 Sep; 90(6):2364-75. PubMed ID: 9310487
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine.
Montillo M; Cafro AM; Tedeschi A; Brando B; Oreste P; Veronese S; Rossi V; Cairoli R; Pungolino E; Morra E
Haematologica; 2002 Jul; 87(7):695-700; discussion 700. PubMed ID: 12091119
[TBL] [Abstract][Full Text] [Related]
20. Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin.
Lynch TJ; Lambert JM; Coral F; Shefner J; Wen P; Blattler WA; Collinson AR; Ariniello PD; Braman G; Cook S; Esseltine D; Elias A; Skarin A; Ritz J
J Clin Oncol; 1997 Feb; 15(2):723-34. PubMed ID: 9053498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
